SCHEMBL4189992

SCHEMBL4189992

N=C(N)NOC(=O)c1ccccc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.58
TSHR P16473 2/20 0.58
HPGD P15428 7/20 0.53
KDM4E B2RXH2 6/20 0.53
HSD17B10 Q99714 5/20 0.53
ALDH1A1 P00352 4/20 0.53
MAPT P10636 1/20 0.53
ALOX15 P16050 1/20 0.50
TDP1 Q9NUW8 2/20 0.49
F2 P00734 1/20 0.47
F10 P00742 1/20 0.47
PLG P00747 1/20 0.47
PLAU P00749 1/20 0.47
PLAT P00750 1/20 0.47
CA1 P00915 3/20 0.47
CA9 Q16790 3/20 0.47
GAA P10253 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MPO P05164 1/20 0.46
HIF1A Q16665 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184146 0.88 ALDH1A1 (0.44) LMNATSHRHPGDKDM4EHSD17B10
SCHEMBL6438478 0.87 LMNA (0.60) LMNATSHRHPGDKDM4EHSD17B10
Hydrochloric Acid SCHEMBL28090977 0.86 ALDH1A1 (0.42) LMNATSHRHPGDKDM4EHSD17B10
SCHEMBL28013496 0.85 LMNA (0.58) LMNATSHRHPGDKDM4EHSD17B10
SCHEMBL27908807 0.81 TSHR (0.63) LMNATSHRHPGDKDM4EHSD17B10
SCHEMBL10667678 0.81 ALDH1A1 (0.61) TSHRHPGDKDM4EHSD17B10ALDH1A1
SCHEMBL6909900 0.81 TSHR (0.53) LMNATSHRHPGDKDM4EHSD17B10
Methyl Salicylate SCHEMBL27460362 0.81 TSHR (0.73) LMNATSHRHPGDKDM4EHSD17B10
SCHEMBL10501149 0.80 LMNA (0.67) LMNATSHRHPGDKDM4EHSD17B10
SCHEMBL6912975 0.80 TSHR (0.56) LMNATSHRHPGDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090004128-A1 Non-Irritant Rapid-Action Dipilatory Composition PRODUCCIONES INFOVISION (MX) 2009-01-01 US claimed
US-12491493-B1 Amine appended bimetallic metal-organic framework (MOF-74) for carbon dioxide capture and method of preparation thereof KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2025-12-09 US disclosed
EP-4088784-A1 COMPOSITION FOR DISINFECTION AND COSMETIC APPLICATIONS Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2022-11-16 EP disclosed
US-9150504-B2 Fatty acid guanidine and salicylate guanidine derivatives and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
US-9150504-B2 Fatty acid guanidine and salicylate guanidine derivatives and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
US-9150504-B2 Fatty acid guanidine and salicylate guanidine derivatives and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
EP-2701509-A4 FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS INC (US) 2015-06-17 EP disclosed
CN-104262204-A Preparation method of guanidine salicylate compound JIANGSU TIANSHENG PHARMACEUTICAL CO LTD 2015-01-07 CN disclosed
CN-104262204-A Preparation method of guanidine salicylate compound JIANGSU TIANSHENG PHARMACEUTICAL CO LTD 2015-01-07 CN disclosed
EP-2701509-A1 FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES Catabasis Pharmaceuticals, Inc. (US) 2014-03-05 EP disclosed
EP-2701509-A1 FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES Catabasis Pharmaceuticals, Inc. (US) 2014-03-05 EP disclosed
EP-2701509-A1 FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES Catabasis Pharmaceuticals, Inc. (US) 2014-03-05 EP disclosed
WO-2012149352-A1 FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-11-01 WO disclosed
WO-2012149352-A1 FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-11-01 WO disclosed
WO-2012149352-A1 FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-11-01 WO disclosed
US-20120277305-A1 FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-11-01 US disclosed
US-20120277305-A1 FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-11-01 US disclosed
US-20120277305-A1 FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-11-01 US disclosed
US-20090004128-A1 Non-Irritant Rapid-Action Dipilatory Composition PRODUCCIONES INFOVISION (MX) 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277305-A1 FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES SCD, SCD5, FASN LMNA 812/4885TSHR 3580/4885HPGD 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.